Abstract
The impact of a 4-week course of therapy with Uralyt-U (potassium-sodium hydrocitrate) on uric acid (UA) metabolic parameters was studied in patients with gout and nephrolithiasis. Elevated daily urinary excretion of UA was found to be directly correlated with its lower serum level after 4-week therapy with Uralyt-U (p < 0.05), resulting in improvement and normalization of UA metabolism. Uralyt-U therapy is safe and causes no worsening of the parameters of hepatic and renal function and electrolyte exchange.
Highlights
Изучено влияние у больных подагрой и нефролитиазом 4-недельного курса терапии препаратом уралит-У на показатели обмена мочевой кислоты (МК)
The impact of a 4-week course of therapy with Uralyt-U on uric acid (UA) metabolic parameters was studied in patients with gout and nephrolithiasis
Elevated daily urinary excretion of UA was found to be directly correlated with its lower serum level after 4-week therapy with Uralyt-U (p < 0.05), resulting in improvement and normalization of UA metabolism
Summary
Изучено влияние у больных подагрой и нефролитиазом 4-недельного курса терапии препаратом уралит-У (калия-натрия гидроцитрат) на показатели обмена мочевой кислоты (МК). Ding C., Garnero P., Cicuttini F. et al Knee cartilage defects: association with early radiographic osteoarthritis, decreased cartilage volume, increased joint surface area and type II collagen breakdown. Jordan K.M., Arden N.K., Doherty M. et al EULAR Recommendations 2003: an evidence based approach to the management of the knee osteoarthritis: Report or a Task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISI).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
